Radiotherapy Dose Adaptation Based on Tumor Biology in Patients With cN2b-N3 Breast Cancer

Launched by SAMSUNG MEDICAL CENTER · May 31, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how the amount of radiation therapy given to women with advanced breast cancer (specifically those with cancer that has spread to nearby lymph nodes) can be adjusted based on how well their tumors respond to initial chemotherapy. The researchers want to find out how this tailored approach affects important outcomes like survival rates, the chance of cancer coming back in the same area, any side effects from the treatment, and the overall quality of life for patients over a five-year period.

To participate in this trial, women must be at least 19 years old, have specific types of breast cancer that have spread to certain lymph nodes, and have already received chemotherapy before surgery. Participants will undergo various assessments to check their health and quality of life before and after radiation treatment. The trial is currently looking for volunteers, so if you or someone you know fits these criteria, it could be a valuable opportunity to help improve future breast cancer treatments.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female with age 19 or older
• • Metastasis to internal mammary and/or supraclavicular lymph nodes, assessed by radiological exams and/or biopsy
• • Underwent neoadjuvant chemotherapy
• • Pathologic confirmation of invasive breast cancer treated with breast conserving surgery or mastectomy
• • Eastern Cooperative Oncology Group performance status 0-2
• • Informed consent
• Exclusion Criteria:
• • Previous history of radiation therapy to the chest
• • Distant metastasis